Imidazole propionate is a driver and therapeutic target in atherosclerosis
17 July 2025Nature, Published online: 16 July 2025; doi:10.1038/s41586-025-09263-w
Imidazole propionate produced by gut microbiota is associated with atherosclerosis in mouse models and in humans, and causes the development of atherosclerosis through activation of the imidazoline-1 receptor in myeloid cells.